|
|
|
市場調查報告書
高含量分析:技術·用途·市場動態
High-Content Analysis: Technologies, Applications, and Market Dynamics
|
高含量分析:技術·用途·市場動態 是由出版商Insight Pharma Reports在2011年12月所出版的。
這份英文市場調查報告書價格從美金1795起跳。
本報告提供高含量分析(HCA)的技術·用途·市場發展的轉變調查分析，HTS·HCS發展的轉變，HCA的實行技術與現在可以利用的系統概要，HCA的利用領域與用途，競爭環境與主要交易/契約的檢驗，對HCA用戶的使用趨勢調查，專家的採訪等彙整資料，為您概述為以下內容。
摘要整理
第1章 簡介
第2章 HCA的發展和HCA的性質
- 從HTS轉變為HCS
- HCS系統的崛起:HCA的徵兆
- HCA/HCS定義
第3章 HCA的技術方面
- HCA平台
- 流式細胞技術
- 活細胞HCA
- 一次細胞與幹細胞
- 資訊學
第4章 HCA的用途
- 細胞信號傳達
- 細胞·有機體生理學
- 毒物學
- 標的識別·評估
- 開發藥劑下的HCS的用途
- 細胞及其他的樣品類型的性質和來源
- 基礎細胞生物學研究·學術的篩檢中心的HCS的用途
第5章 市場動態
- 競爭環境
- 各種契約
- 用戶調查
- 頭銜
- 配合措施
- 組織類型
- 用途與利用頻率
- 疾病分類
- 設備的點閱存取性
- 設備的類型
- 設備的地點
- 樣品類型·方式的利用的頻率
- 試劑的採購的頻率
- 設備的參數·屬性的重要性
- 觀察
第6章 市場觀察與趨勢
- 大企業的HCA的興趣
- 促使未來市場成長的必要條件
- 對HCA的藥物發明的影響
- 總論
第7章 專家的採訪
索引
企業目錄
圖表
Abstract
This Insight Pharma Report focuses on the applications, technology and market
aspects of high-content analysis (HCA) - a field that originated when
automated microscopic imaging technology joined with the high-throughput
screening paradigm that signified the birth of “industrialized drug
discovery”.
This report discusses:
- Development of the HCA field from the commercial, scientific, and
technological perspectives
- Technologies that underlie HCA and the full range of systems that are
available today
- Applications of HCA in areas including cell signaling, cell and organism
physiology, toxicology, target validation, and drug discovery
- Market dynamics, including a competitive analysis and an examination of
recent HCA deals
- Results from an Insight Pharma Reports online survey of people who are
active in the HCA field
- Interviews with individuals who are highly knowledgeable in the HCA field,
which were conducted exclusively for this report
High-throughput screening (HTS), used for the en masse discovery of compounds
that interact with molecular drug targets, provides many more hits than viable
drug candidates. In the last decade, HCS (high-content screening), based
largely on automated imaging technology, has come to provide a form of
secondary screening in which hits can be tested efficiently for their effects
on cells. Applications of HCS have diversified into what is now called HCA
(high-content analysis), a more generalized term that covers areas such as
target identification, pathway analysis, mechanism of action verification, and
cell biology research in general.
High-Content Analysis: Technologies, Applications, and Market Dynamics begins
by examining the evolution and nature of HCA. The several variant definitions
of HCA/HCS that have been offered are addressed, before turning to an
examination of the technological aspects of HCA. In addition to automated
microscopic imaging systems, also covered are flow cytometry from the HCA
perspective, live cell and kinetic HCA, the role of primary cells and stem
cells, and the nature of informatics systems supporting HCA investigations.
This report next addresses HCA applications in areas that include cell
signaling, cell and organism physiology, toxicology, and target identification
and validation before turning specifically to applications in drug discovery,
including primary and secondary screening. Other topics covered are the role
of service organizations, the nature and sources of cells and other sample
types, and applications in cell biology research.
High-Content Analysis: Technologies, Applications, and Market Dynamics then
turns to an analysis of market dynamics in terms of the competitive landscape
among vendors, deals and deal patterns, and results from a survey of
individuals who use HCA. We conclude by summarizing our findings, discussing
possible future directions in the HCA field, and addressing the key questions:
- Why are so many large companies interested in HCA?
- What do HCA systems manufacturers need to do to keep the market growing at
a healthy clip?
- Is HCA making a significant impact on drug discovery?
About the Author
Ken Rubenstein, PhD, a biochemist and molecular biologist, received his
PhD at the University of Wisconsin and postdoctoral training at the University
Of Pennsylvania School Of Medicine. He was a key innovator and research
manager for Syva Company, the diagnostics branch of Syntex Corporation. During
his 13 years with Syva, Dr. Rubenstein became vice president, scientific
affairs, and a function that included strategic planning. Since 1983, he has
served as a technology and marketing consultant to biomedical companies and an
industry analyst, with more than 40 published studies to his credit.
Table of Contents
Executive Summary
- Evolution of the Field and Definitions
- Technological Aspects of HCA
- HCA Applications
- Market Dynamics
- Observations and Trends
Chapter - 1
- Introduction
- Scope and Format of the Report
Chapter - 2
- Evolution and Nature of HCA
- HTS Gives Rise to HCS
- The Rise of HCS Systems: A Prelude to HCA
- HCA/HCS Definitions
Chapter - 3
- Technological Aspects of HCA
- 3.1. HCA Platforms
- 3.2. Flow Cytometry
- 3.3. Live Cell HCA
- 3.4. Primary and Stem Cells
- 3.5. Informatics
- Third-Party Software
- Open-Source Software
Chapter - 4
- HCA Applications
- 4.1. Cell Signaling
- 4.2. Cell and Organism Physiology
- 4.3. Toxicology
- 4.4. Target Identification and Validation
- 4.5. Applications of HCS in Drug Discovery
- Primary HCS Testing
- Secondary HCS
- Service Organizations
- 4.6. Nature and Sources of Cells and Other Sample Types
- Cells
- Tissues and Surrogates
- Organisms
- 4.7. Applications of HCS in Basic Cell Biology Research and
Academic Screening Centers
Chapter - 5
- Market Dynamics
- 5.1. Competitive Landscape
- 5.2. Deals
- 5.3. User Survey
- Title
- Activity
- Type of Organization
- Application Usage Frequency
- Disease Categories
- Instrument Access
- Instrument Type
- Instrument Location
- Frequency of Employing Sample Types and Assay Modalities
- Reagent Sourcing Frequency
- Importance of Instrument Parameters and Attributes
Chapter - 6
- Observations and Trends
- 6.1. Large Company Interest in HCA
- 6.2. Requirements for Future Market Growth
- 6.3. HCA's Impact on Drug Discovery
- 6.4. Conclusion
Chapter - 7
- Expert Interview Transcripts
- 7.1. Joseph Zock, IntelliCyt Corporation, Senior Director Product
Management
- 7.2. Mark Collins, PhD, Director of Global Marketing for Life
Science Research, Cellomics
- 7.3. William Busa, PhD, President, Busa Consulting
- 7.4. Leo Bleicher, Product Manager, Imaging Component Collection,
Accelrys
- 7.5. Michelle Palmer, PhD, Director of Discovery and Preclinical
Research, Broad Institute
- 7.6. Evan Cromwell, PhD, Director of Research, Molecular Devices
References
Company Index
TABLES
- Table 3.1. Identity and attributes of some HCA systems
- Table 3.2. Software Provided by Systems Manufacturers
- Table 3.3. Open-Source Software for HCA/HCS
- Table 5.1. Selected recent HCS/HCA deals
- Table 5.2. Frequency (%) with which respondents are involved with
particular applications
- Table 5.3. Frequency (%) with which respondent employs indicated sample
type or assay modality
- Table 5.4. Frequency (%) with which respondent plans to employ indicated
sample type or assay modality in the next two years
- Table 5.5. Frequency (%) with which respondents use three sources of
reagents
- Table 5.6. Importance of instrument parameters/attributes
FIGURES
- Figure 3.1. Diagram of confocal principle
- Figure 3.2. BD Biosciences 855, schematic of the light path
- Figure 3.3. The CompuCyte iCys LSC system in schematic
- Figure 5.1. Respondents' position in the HCS/HCA field
- Figure 5.2. Nature of respondents' work in the HCS/HCA field
- Figure 5.3. Nature of respondents' organization
- Figure 5.4. Respondents' disease categories
- Figure 5.5. Number of HCS/HCA instruments onsite in organization
- Figure 5.6. Number of HCS/HCA instruments respondent has access to
- Figure 5.7. Dominant instrument type to which respondent has access for
HCS/HCA
- Figure 5.8. Location of instruments to which respondent has access
|
 |
